James Ellsmore, Author at King & Wood Mallesons Pulse

Justice Jagot rejects ‘manifestly absurd and unreasonable’ construction of new copyright exemption for PI documents

25 November 2011

When Justice Jagot handed down her judgment in Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 3) in August this year (read our Alert here, her Honour found that Apotex’s proposed supply of a generic leflunomide product would infringe Sanofi’s patent.

Read on

Natco pushes ahead with bid to compulsorily licence anti-cancer drug from Bayer

27 September 2011

By James Ellsmore

Natco Pharma, an Indian generic pharmaceutical company, has lodged an application with the Indian Patent Office requesting the grant of a compulsory licence to produce a generic version of Bayer’s anti-cancer drug Nexavar.

Read on

Senate Committee throws its support behind opponents of the Gene Patents Bill

26 September 2011

By James Ellsmore

Read on

US Senate passes patent reform measures

13 September 2011

By James Ellsmore

The New York Times reported last week that the US Senate has passed a bill to bring about a suite of changes to the American patent system.

Read on

TGA gets tough on sponsors who fail to comply with advertising rules

11 August 2011

By James Ellsmore

Sponsors beware!

Read on

Review Panel prescribes greater transparency for the TGA

3 August 2011

By James Ellsmore

Last month, the Parliamentary Secretary for Health & Ageing, the Hon Catherine King MP, released a Report into ways of improving the transparency of the Therapeutic Goods Administration.

Read on

Myriad Genetics 1 versus ACLU 1 in US gene patents battle

3 August 2011

By James Ellsmore

In a decision that’s sure to find its way to the Supreme Court, the US Court of Appeals for the Federal Circuit has ruled that isolated genetic sequences are patentable.

Read on

Australia and New Zealand move closer to joint regulation of medicines and medical devices

23 June 2011

By James Ellsmore

On Monday, the Prime Minister Julia Gillard, and her New Zealand counterpart John Key, announced that both countries had signed a statement of intent to create a joint authority to regulate medicines and medical devices in both countries.

Read on

They’re at it again… Australian biotech company pursues alleged infringers in the US

6 June 2011

By James Ellsmore

Australian biotech company Genetic Technologies (GTG) has announced that it has launched a third round of litigation against US biotech and life sciences companies it says are infringing its patented non-coding DNA technology.

Read on

Competition regulators continue their campaign against pharmaceutical companies

1 June 2011

By James Ellsmore

Last month, the US Federal Trade Commission (FTC) released its findings on reverse payment settlements between pharmaceutical companies in the 2010 US fiscal year.

Read on

Posts From This Author